STIMIT
STIMIT is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at STIMIT.
STIMIT is a company.
Key people at STIMIT.
STIMIT AG is a Swiss medical technology startup founded in 2018, specializing in noninvasive diaphragm neurostimulation to strengthen respiratory muscles in artificially ventilated patients, addressing diaphragm atrophy and dysfunction in intensive care.[2][4] The company develops a medical device platform that uses electromagnetic fields to stimulate the diaphragm, aiming to make ventilation gentler, reduce recovery times, and revolutionize critical care; it serves ICU patients on mechanical ventilation and plans commercial launch in 2025 with ongoing FDA IDE pivotal trials enrolling patients.[1][2][3][4]
Dräger, a global leader in medical and safety technology, acquired a majority stake in STIMIT to accelerate product development and clinical evidence generation, combining startup innovation with Dräger's ventilation expertise; early investors achieved a 3-fold return in under a year, signaling strong growth momentum ahead of commercialization.[1][2][3]
STIMIT was founded in 2018 in Biel/Bienne, Switzerland, by Ronja Müller-Bruhn (CEO) and Oliver Müller, who identified the need for solutions to preserve diaphragm function in ventilated patients, a critical issue causing atrophy and prolonged recovery.[2][4] The idea emerged from recognizing gaps in respiratory care, leading to development of noninvasive electromagnetic stimulation technology; early traction came via CHF 150K from Venture Kick Life Sciences in 2020, the first medtech award under that program, and a 2022 strategic cooperation with neurocare group AG.[4][5]
Pivotal moments include Dräger's majority acquisition (date not specified in sources, but post-2020 based on context), securing development head start, and launching the FDA IDE "STIMIT ACTIVATOR 1 PIVOTAL STUDY" for clinical validation with renowned centers.[1][2][4]
STIMIT stands out in respiratory critical care through:
STIMIT rides the wave of advancements in noninvasive respiratory therapies, amid rising demand for gentler ventilation alternatives post-COVID, where diaphragm dysfunction affects up to 80% of prolonged ICU cases (inferred from context of atrophy risks).[1][2][4] Timing aligns with regulatory progress—FDA IDE approval and 2025 commercialization—capitalizing on market forces like aging populations, chronic respiratory diseases, and medtech consolidation by incumbents like Dräger seeking innovation edges.[1][2][3]
It influences the ecosystem by pioneering muscle-preserving tech, potentially shortening ICU stays, reducing costs, and enabling earlier weaning from ventilators; Dräger's involvement accelerates adoption in 190+ countries, while trials set precedents for neurostimulation in critical care.[1][2][4]
STIMIT is poised for breakout in 2025 with commercial rollout, pivotal trial results, and fresh investments fueling scale; success hinges on generating clinical evidence to prove superiority over standard ventilation.[2][3][4] Trends like AI-enhanced medtech, personalized critical care, and noninvasive shifts will amplify its trajectory, potentially evolving from niche startup to platform leader via Dräger's network.
Watch for trial outcomes and partnerships—these could cement STIMIT as a game-changer, tying back to its core mission of transforming ventilation from a blunt tool to a muscle-preserving therapy.[1][2]
Key people at STIMIT.
